Jeffrey Ubben
ValueAct Holdings
ValueAct Holdings Portfolio 13F
Jeffrey Ubben Holdings Activity
- Portfolio value:
- $9.88B≈ (-$94M≈)
- Previous value:
- $9.98B≈
- # of changes:
- 10
- New positions:
- 2
- Reported for:
- 31 Dec 2017 (Q4)
- Latest filing date:
- 15 Feb 2018
ValueAct Holdings has disclosed a total of 10 changes to the portfolio in the (2017 Q4) SEC report(s): increased the number of shares of 4, bought 2 totally new, decreased the number of shares of 1 and completely sold out 3 position(s).
What stocks did Jeffrey Ubben buy in 2017 Q4?
During 2017 Q4 Jeffrey Ubben has bought 6 securities out of which top 5 purchases (by % change to portfolio) were (KKR) KKR & Co Inc (added shares +4.82%), (MS) Morgan Stanley (added shares +0.42%), (MSFT) Microsoft Corp (added shares +0.01%), (TRN) Trinity Industries Inc (added shares +7.84%) and (ESRX) Express Scripts Holding Co (new buy).
10 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Citigroup Inc
|
new
|
$74.41
|
+84.06%($136.96)
|
0.83%
|
2017 Q4
|
≈ 0.25 years
|
||||
|
|
Express Scripts Holding Co
|
new
|
$74.64
|
|
0.91%
|
2017 Q4
|
≈ 0.25 years
|
||||
|
|
Trinity Industries Inc
|
+7.84%
|
$37.46
|
-14.95%($31.86)
|
7.05%
|
2016 Q2
|
≈ 1.75 years
|
||||
|
|
KKR & Co Inc
|
+4.82%
|
$21.06
|
+411.02%($107.62)
|
10.18%
|
2017 Q2
|
≈ 0.75 years
|
||||
|
|
Morgan Stanley
|
+0.42%
|
$52.47
|
+315.78%($218.16)
|
9.53%
|
2016 Q2
|
≈ 1.75 years
|
||||
|
|
Microsoft Corp
|
+0.01%
|
$85.54
|
+479.83%($495.99)
|
7.80%
|
2013 Q2 or earlier
|
≈ 4.75+ years
|
||||
|
|
CBRE Group Inc, CL-A
|
-13.72%
|
$43.31
|
+245.30%($149.55)
|
10.92%
|
2013 Q2 or earlier
|
≈ 4.75+ years
|
||||
|
|
Willis Towers Watson PLC
|
-100%
|
$154.23
|
+118.66%($337.24)
|
0.00%
|
2016 Q1
|
≈ 1.75 years
|
||||
|
|
Baker Hughes Co
|
-100%
|
$36.62
|
+67.91%($61.49)
|
0.00%
|
2017 Q3
|
≈ 0.25 years
|
||||
|
|
Bioverativ Inc
|
-100%
|
$57.07
|
|
0.00%
|
2017 Q1
|
≈ 0.75 years
|
||||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.